Resyca https://validator.w3.org/feed/docs/rss2.html Quality & Regulatory News Home Our Leadership Partnering Evaluation of Rayleigh jet atomiser for intranasal delivery of lipid nanoparticle – siRNA formulations: stability, deposition, and device performance Resyca® Soft Nasal Spray Adaptor: low shear forces and optimal nasal coverage Soft Nasal Spray Adaptor Pulmospray PFSI Resyca® PFSI™ Soft Mist Inhaler (SMI): Inhalation spray in a convenient device Resyca® Pulmospray™ Soft Mist Inhaler (SMI): fast preparation and breath-synchronised delivery Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterisation, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis Soft mist inhaler nebulisation by Rayleigh-breakup largely preserves functional integrity of liposomal mRNA in respirable aerosols SMIs & Soft Mist Nasal Sprays – A key defence in the fight against the next pandemic? Inhalation delivery of complex drugs – the next steps Degradation of lipid based drug delivery formulations during nebulisation Aerosol performance of the single-use Pulmospray soft mist inhaler for inhalation of high amounts of liquid formulations Early effects of low molecular weight heparin therapy with soft mist inhaler for COVID-19-Induced Hypoxemia: A phase IIb trial Do soft mist inhalers hold the key to faster inhalation drug development? Fluorescence-enabled evaluation of nasal tract deposition and coverage of pharmaceutical formulations in a silicone nasal cast using an innovative spray device Low energy nebulisation preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery Improved olfactory deposition of theophylline using a nanotech soft mist nozzle chip Transforming the biologics product lifecycle with inhalation innovation How soft mist inhalers support improved biopharma drug delivery Pulmonary delivery of favipiravir in rats reaches high local concentrations without causing oxidative lung injury or systemic side effects Advances in soft mist inhalers Cyrano Therapeutics and Resyca announce exclusive license agreement for soft mist nasal spray technology for the treatment of persistent smell loss Influence of fluid physiochemical properties on aerosolisation performance of a novel soft mist inhaler Resyca receives medical device regulation certificate from TÜV SÜD Assessment of the delivery performance of a novel soft mist inhaler using a pre-filled syringe based container closure system Publications Assessing the variability of in silico lung deposition predictions when inhaling from soft mist inhalers with various air flow resistances A device screening method for predicting delivery of inhaled mRNA via a nebuliser Assessment of the novel soft mist Pre-filled Syringe Inhaler (PFSI) device performance after storage at sub 0 °C temperature conditions Pre-filled syringe soft mist nasal spray for improved intranasal drug delivery Targeted nasal delivery of LNP-mRNAs aerosolised by Rayleigh breakup technology Rayleigh-based soft mist inhalers preserve mRNA-LNP integrity for pulmonary delivery Enhancing drug delivery with innovative soft mist inhaler technology Technology Resyca BV successfully recertified for ISO 13485 – valid until 2028 Resyca Announces the Appointment of Deborah Jones as New CEO Usability and inspiratory flow profiles of patients with pulmonary hypertension inhaling with a novel Soft Mist Inhaler (SMI) Ultra Soft Nasal Pump Spray Contact Us Silo Pharma and Resyca BV partner on device and CMC development for intranasal PTSD drug SPC-15 Spray nozzle unit high volume manufacturing at Medspray Successful phase 2/3 study with Heparin delivered with Pulmospray Bespak – device manufacturing About Us